Executive Summary
Regulatory affairs is becoming increasingly complex as pharmaceutical companies operate across more markets, manage larger submission volumes, and navigate constantly evolving regulatory expectations.
Regulatory teams must monitor changing requirements, interpret guidance, prepare submissions, maintain documentation, and coordinate information across clinical, medical, quality, manufacturing, and commercial functions.
Artificial intelligence is beginning to reshape these activities.
AI can analyze large volumes of regulatory information, identify relevant changes, compare documents, support submission preparation, and help teams retrieve information more efficiently. Generative AI adds another capability by assisting with drafting, summarization, and document review.
The opportunity is not to automate regulatory judgment. Regulatory decisions require qualified professionals, scientific context, and accountability. Instead, AI can reduce repetitive work and provide regulatory teams with better intelligence.
As submission requirements and data volumes continue to grow, AI could help regulatory affairs evolve from a largely document-intensive function into a more predictive, connected, and strategic capability.
Why Is Regulatory Affairs Becoming More Complex?
Pharmaceutical companies operate within a global regulatory environment involving multiple agencies, jurisdictions, product categories, and submission requirements.
A single development program can generate extensive documentation across clinical development, safety, manufacturing, quality, and medical functions.
Regulatory teams must ensure that information is accurate, consistent, current, and appropriately presented.
At the same time, regulatory requirements continue to evolve.
Manually monitoring these changes and assessing their implications can consume significant resources.
AI provides an opportunity to process regulatory information at a scale that would be difficult for human teams alone.
How Can AI Improve Regulatory Intelligence?
Regulatory intelligence involves monitoring regulations, guidance, agency communications, approvals, safety developments, and other external information.
AI can continuously analyze large volumes of regulatory content and identify information potentially relevant to specific products or development programs.
Natural language processing can help classify documents and identify changes in regulatory language.
AI can also summarize lengthy guidance and highlight sections requiring closer review.
This could allow regulatory professionals to spend less time searching for information and more time interpreting its implications.
Can AI Accelerate Regulatory Submissions?
Regulatory submissions involve extensive documentation and coordination.
AI can support teams by organizing information, identifying relevant source materials, comparing versions, and helping draft sections based on approved information.
Generative AI can also assist with summarization and document transformation.
For example, the same underlying information may need to be presented in different formats across regulatory documents.
AI can help accelerate these activities while reducing some manual effort.
However, AI-generated content must remain subject to appropriate review because even small inaccuracies can create significant regulatory consequences.
How Is AI Changing Regulatory Document Review?
Regulatory professionals spend substantial time reviewing documents for consistency, completeness, and accuracy.
AI can compare documents and identify differences, conflicting information, missing sections, or terminology inconsistencies.
It can also help identify references that may require verification.
This is particularly valuable when large submission packages contain information originating from multiple functions.
By highlighting potential issues before submission, AI could reduce the amount of manual checking required while improving the consistency of regulatory documentation.
What Role Can Generative AI Play?
Generative AI is particularly relevant to regulatory affairs because much of the function involves complex text and information.
Large language models can summarize regulatory guidance, draft preliminary content, answer questions based on approved internal sources, and help employees navigate large document repositories.
However, regulatory organizations should avoid treating generic AI systems as authoritative sources.
Enterprise implementations should prioritize controlled information environments, approved sources, traceability, and human review.
The most valuable systems may be those that combine generative capabilities with pharmaceutical-specific data and governance.
Can AI Improve Regulatory Compliance?
AI could help organizations monitor compliance requirements more continuously.
Systems can analyze internal documents and processes against defined requirements and identify potential gaps for review.
AI can also help track regulatory commitments, submission deadlines, and changes that may require action.
This creates an opportunity to move from periodic compliance reviews toward more continuous monitoring.
The objective is not to allow AI to determine compliance independently. Rather, AI can help regulatory teams identify where human attention is most needed.
How Could AI Support Labeling?
Product labeling is a highly controlled regulatory activity.
Changes to safety information, indications, dosing, or other product information can require extensive review and coordination.
AI can help compare labeling documents, identify inconsistencies, track changes, and retrieve relevant information from approved sources.
It can also help teams understand how changes in one document may relate to information elsewhere in the regulatory package.
Because labeling directly affects information provided to healthcare professionals and patients, final decisions and approvals must remain under appropriate human control.
Can AI Help Manage Regulatory Data?
Regulatory affairs increasingly depends on structured information as well as documents.
Product information, submission components, commitments, agency interactions, and other regulatory data may be distributed across multiple systems.
AI can help connect these information sources and make them easier to search and analyze.
This can provide regulatory teams with a more complete view of a product’s regulatory history.
Combined with a unified data platform, AI could eventually enable regulatory professionals to move from searching for information to receiving relevant insights proactively.
How Can AI Support Global Regulatory Strategy?
Regulatory strategies often need to account for differences between markets.
AI can analyze requirements across jurisdictions and identify areas of similarity and divergence.
This could help teams assess potential submission strategies earlier in development.
AI may also support scenario analysis by helping regulatory professionals compare different approaches and identify potential requirements that could affect timelines or evidence generation.
Human regulatory expertise remains essential, but AI can make the information-gathering process faster and more comprehensive.
What Are the Risks of AI in Regulatory Affairs?
AI adoption creates important risks.
Generative AI systems can produce inaccurate information, misunderstand regulatory language, or generate unsupported claims.
There are also concerns around data privacy, intellectual property, cybersecurity, model transparency, and the use of outdated information.
For regulatory affairs, traceability is particularly important.
Professionals need to know where AI-generated information came from and whether it is supported by an authoritative source.
AI systems should therefore operate within clearly defined governance frameworks.
How Should Pharma Govern Regulatory AI?
Pharmaceutical companies should establish controls based on the risk of each AI application.
Systems used for document search or internal summarization may require different controls from AI supporting submission content or regulatory decision-making.
Governance should address data sources, access permissions, model validation, output verification, audit trails, change management, and human accountability.
Companies should also ensure that employees understand the limitations of AI.
The objective is to create a controlled environment where AI accelerates regulatory work without undermining the reliability of regulatory information.
What Should Regulatory Leaders Do Now?
Regulatory organizations should start with high-volume, relatively structured activities where AI can provide measurable value.
Regulatory intelligence, document comparison, content retrieval, submission support, and information summarization can provide practical entry points.
Leaders should also identify processes where regulatory professionals spend significant time performing repetitive information-management tasks.
The goal should be augmentation.
AI should allow regulatory experts to devote more time to strategy, interpretation, agency interactions, and complex decision-making.
What Will the Future of Regulatory Affairs Look Like?
The regulatory affairs function could become increasingly predictive and proactive.
AI systems may continuously monitor external regulatory developments, assess their potential relevance, and alert teams before changes create operational challenges.
Submission teams could work with AI assistants that retrieve approved information, identify inconsistencies, and support document preparation.
Regulatory professionals could also have a more connected view of product information across development and commercialization.
This would shift regulatory affairs from a document-centered function toward an intelligence-driven capability.
Conclusion
AI is transforming regulatory affairs by changing how pharmaceutical companies manage information, prepare submissions, monitor requirements, and support compliance.
The technology can reduce manual document work, accelerate regulatory intelligence, improve consistency, and help teams identify potential issues earlier.
But regulatory affairs is not simply an information-processing function.
It requires judgment, scientific understanding, interpretation, and accountability. AI should therefore enhance regulatory expertise rather than attempt to replace it.
The companies that benefit most will be those that combine AI with strong data foundations, controlled information sources, rigorous governance, and experienced regulatory professionals.
As regulatory environments become more complex, AI could become the intelligence layer that helps regulatory teams move faster while maintaining the accuracy, traceability, and control that pharmaceutical regulation demands.
Artificial intelligence is rapidly changing how Pharma companies manage regulatory affairs. From reviewing large volumes of scientific information to preparing submissions and monitoring compliance, AI can reduce repetitive work while helping regulatory teams make faster, data-driven decisions.
The FDA has already established a risk-based approach for evaluating AI-generated information used to support regulatory decisions involving drug safety, effectiveness, and quality.
AI-Powered Regulatory Submissions
One of the most important applications of AI in Pharma regulatory affairs is submission preparation. AI systems can organize information, identify missing documentation, compare regulatory requirements, and assist teams in creating consistent submission packages.
Natural language processing can also help regulatory professionals analyze large collections of guidance documents, clinical reports, scientific publications, and previous submissions. This can make regulatory research significantly more efficient.
Faster Regulatory Data Review
Pharma organizations generate enormous amounts of clinical, manufacturing, safety, and quality data. AI can rapidly process these datasets and highlight patterns, inconsistencies, and potential compliance issues.
Instead of manually reviewing every document, regulatory professionals can use AI to prioritize areas requiring closer human attention. This allows specialists to spend more time on strategic decisions and scientific judgment.
Improving Compliance Management
Regulatory requirements continue to evolve across global markets. AI can help Pharma teams track regulatory changes, compare requirements between jurisdictions, and identify potential gaps in existing processes.
AI-based systems can also support document classification, regulatory intelligence, and workflow automation. However, human oversight remains essential because regulatory decisions require accountability, context, and professional judgment.
AI and Regulatory Intelligence
Regulatory intelligence is another area where AI can deliver significant value for Pharma companies. AI tools can analyze regulatory announcements, guidance updates, scientific literature, and historical decisions to help teams identify emerging trends.
This can give regulatory affairs professionals earlier visibility into changing expectations and help organizations prepare their development and submission strategies.
Risk, Validation, and Human Oversight
The adoption of AI in Pharma regulatory affairs also creates new responsibilities. AI-generated information must be reliable, traceable, and appropriate for its intended use.
The FDA’s current framework emphasizes establishing the credibility of AI models for a specific context of use. In January 2026, FDA and EMA also published ten guiding principles for good AI practice in drug development, highlighting responsible implementation across the product lifecycle.
The Future of Pharma Regulatory Affairs
AI is unlikely to replace regulatory professionals. Instead, it will increasingly act as an intelligent support layer that helps teams process information, automate repetitive activities, identify risks, and prepare better decisions.
For Pharma companies, the greatest opportunity will come from combining AI capabilities with strong data governance, validated processes, regulatory expertise, and human review. Organizations that establish these foundations can use AI to build faster, more consistent, and more adaptable regulatory operations.
AI for Global Regulatory Strategy
AI is helping Pharma companies manage regulatory requirements across multiple countries. Regulatory teams can use intelligent systems to compare submission requirements, identify differences between markets, and organize country-specific documentation. This can reduce duplication and help teams build more consistent global strategies.
Smarter Document Management
Regulatory departments handle thousands of documents throughout the development and approval lifecycle. AI can classify documents, extract important information, identify duplicate content, and connect related records. For Pharma organizations, this creates a more searchable and organized regulatory environment.
AI for Labeling and Safety Information
Product labeling requires accuracy and consistency. AI can assist Pharma teams by comparing labels across regions, identifying potential inconsistencies, and tracking changes. AI can also help regulatory professionals review safety information and organize adverse-event data for further assessment.
Supporting Regulatory Writing
AI-powered writing tools can assist Pharma regulatory teams with repetitive documentation tasks. These systems can help summarize clinical information, structure reports, and identify missing sections. Human regulatory experts should continue to review and approve final content to ensure scientific accuracy and compliance.
Real-Time Regulatory Monitoring
Regulatory intelligence is becoming increasingly dynamic. AI can monitor new guidance, announcements, scientific developments, and policy changes. This gives Pharma organizations an opportunity to identify important regulatory developments earlier and adjust strategies before changes create operational delays.
AI Across the Drug Development Lifecycle
AI is no longer limited to a single regulatory activity. The FDA says it has seen a significant increase in drug application submissions containing AI components across nonclinical, clinical, postmarketing, and manufacturing stages.
This broader adoption means Pharma regulatory teams increasingly need to understand how AI-generated evidence is created, validated, documented, and communicated to regulators.
Building Trust in AI Systems
Trust will be one of the biggest factors shaping AI adoption in Pharma regulatory affairs. Companies need clear governance policies covering data quality, model performance, validation, access controls, audit trails, and human oversight.
